{"entity":{"id":"plb-002","kind":"drug","name":"PLB-002","aka":[],"tldr":"PLB-002 is an experimental antibody-drug conjugate from PrimeLink BioTherapeutics, in phase 1 trials for ovarian cancer, non-small cell lung cancer and CLDN6-positive solid tumours.","summary":"PLB-002 is an antibody-drug conjugate from PrimeLink BioTherapeutics. An antibody-drug conjugate against Claudin 6, a tight junction protein expressed in some solid tumours (notably ovarian, non-small cell lung, endometrial and testicular cancers) and barely in healthy adult tissue. Built on the company's ENHANMIX platform. Its furthest stage is phase 1, for ovarian cancer, non-small cell lung cancer and CLDN6-positive solid tumours. ClinicalTrials.gov registers it in one study linked below. First patient dosed in phase 1 (company release published 2026-02-26); NCT07304128 recruiting per v2 API. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"PrimeLink BioTherapeutics: en.primelinkbio.com","url":"http://en.primelinkbio.com/news_detail/13.html"},{"label":"PrimeLink BioTherapeutics: en.primelinkbio.com","url":"http://en.primelinkbio.com/news_detail/13.html"},{"label":"PrimeLink BioTherapeutics: primelinkbio.com","url":"https://www.primelinkbio.com/pipeline/1.html"},{"label":"PrimeLink BioTherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07304128"},{"label":"ClinicalTrials.gov: trials of PLB-002","url":"https://clinicaltrials.gov/search?intr=PLB-002"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cldn6"],"drugs":[],"companies":["primelink-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07304128"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PLB-002","modality":"Antibody-drug conjugate","mechanism":"An antibody-drug conjugate against Claudin 6, a tight junction protein expressed in some solid tumours (notably ovarian, non-small cell lung, endometrial and testicular cancers) and barely in healthy adult tissue. Built on the company's ENHANMIX platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/plb-002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/"}],"company":[{"id":"primelink-biotherapeutics","kind":"company","name":"PrimeLink BioTherapeutics","route":"/companies/primelink-biotherapeutics/"}],"trial":[{"id":"nct07304128","kind":"trial","name":"A Study of PLB-002 in Advanced Solid Tumors","route":"/trials/nct07304128/"}]}}